NAPRT and neoplasm: These results support the superior anti-tumor efficacy of A4276 over KPT-9274, regardless of NA supplementation, and suggest that A4276 has significant potential as a safe and effective NAMPT inhibitor for the treatment of NAPRT-deficient EMT cancers.